Gradual age-related hearing loss (presbycusis) is common, affecting an estimated one-third of individuals between the ages of 65 and 75, and close to one-half of those older than 75, according to the NIH. There are many possible causes, including complex changes along the nerve pathways leading to the brain.

LCT is developing NTCELL to treat hearing loss by stimulating and protecting these nerve pathways. In studies conducted with the Bionic Ear Institute (BEI) in Melbourne, LCT’s encapsulated porcine choroid plexus cells have been shown to protect nerve cells in the inner ear from degeneration.